Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Last year, nearly half a million cancer patients received life-saving treatments, from a medicine, that's active ingredient was created at Mizzou.

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Pluvicto’s (lutetium Lu 177 vipivotide tetraxetan) dosage for metastatic prostate cancer is 7.4 GBq given every 6 weeks. It’s important to follow the Pluvicto dosage your doctor prescribes.

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen (PSMA ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

Lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) received an expanded indication, which allows the radioligand therapy to be used after one androgen receptor pathway inhibitor (ARPI), as ...

The field is now looking to address patients that do not respond or progress after Pluvicto therapy. We believe ATNM-400 can address this high unmet need and we are incredibly excited by our data ...